Kyverna Therapeutics (KYTX) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
27 May, 2026Opening remarks and agenda
2026 described as a pivotal year with transition to commercial stage and regulatory progress for mivocabtagene in autoimmune diseases.
Meeting called to order with CEO as Chairman and CFO as Secretary; introduction of independent auditor from BDO USA.
Agenda included election of two Class II directors and ratification of the independent auditor.
Board and executive committee updates
Board nominated Ian Clark and Christi Shaw for re-election as Class II directors, with no other nominations received.
Shareholder proposals
No shareholder proposals were received for this year's meeting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Kyverna Therapeutics
- Transformative CAR-T therapy for SPS nears launch, with expansion into MG and MS underway.KYTX
H.C. Wainwright 4th Annual BioConnect Investor Conference19 May 2026 - Miv-cel delivers durable, drug-free remission in SPS and gMG with strong safety and scalability.KYTXInvestor presentation12 May 2026
- Rolling BLA for miv-cel in SPS underway, strong trial results, and solid cash position.KYTXQ1 202612 May 2026
- Miv-cel achieved robust, durable efficacy and drug-free remission in SPS and gMG, supporting launch.KYTXStatus update22 Apr 2026
- Vote on two director seats and auditor ratification at the 2026 annual meeting.KYTXProxy filing13 Apr 2026
- Proposals include director elections and auditor ratification, with strong governance and ESG oversight.KYTXProxy filing13 Apr 2026
- Miv-cel demonstrates transformative efficacy in autoimmune diseases, targeting SPS and gMG first.KYTXCorporate presentation26 Mar 2026
- Shelf registration enables up to $300M in offerings, targeting autoimmune therapy growth.KYTXRegistration filing26 Mar 2026
- BLA filing for first-in-class CAR T in SPS expected 1H 2026, with $279M cash runway into 2028.KYTXQ4 202526 Mar 2026